Incyte Corporation reported its fourth-quarter 2024 financial results, revealing total revenues of $1.2 billion, a 16% increase year-over-year, and full-year revenues of $4.2 billion, up 15% from 2023. The company's non-GAAP diluted earnings per share (EPS) stood at $1.43. Incyte's revenue growth was attributed to strong sales of its products, particularly Jakafi, which generated $773 million in sales, marking an 11% increase year-over-year, and Opzelura, which saw sales of $162 million, a 48% rise. However, the adjusted EPS of $1.43 fell short of the $1.56 estimate, while sales of $1.18 billion exceeded expectations of $1.14 billion. Looking ahead, Incyte provided guidance for 2025, projecting Jakafi sales between $2.925 billion and $2.975 billion, aligning with consensus estimates. The company also noted an upcoming filing for Zynyz in anal cancer, with approval anticipated in the second half of 2025.